XNASSNDX
Market cap1.12bUSD
Jan 10, Last price
13.11USD
1D
-5.07%
1Q
-31.47%
Jan 2017
82.85%
IPO
10.63%
Name
Syndax Pharmaceuticals Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
22.63%
Rev. gr., 5y
19.26%
Revenues
0k
Net income
-209m
L+45.64%
CFO
-161m
L+20.14%
Earnings
Feb 25, 2025
Profile
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | 163,044 | 152,211 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (163,044) | (152,211) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (5,589) | ||||||||
Tax Rate | |||||||||
NOPAT | (163,044) | (146,622) | |||||||
Net income | (209,360) 45.64% | (143,749) -676.70% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 258,094 | 181,791 | |||||||
BB yield | -16.97% | -11.76% | |||||||
| Debt | |||||||||
Debt current | 1,047 | 439 | |||||||
Long-term debt | 2,223 | 1,883 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | (604,142) | (484,418) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (160,601) | (133,675) | |||||||
CAPEX | (225) | ||||||||
Cash from investing activities | 117,609 | (186,188) | |||||||
Cash from financing activities | 264,132 | 172,254 | |||||||
FCF | (163,480) | (146,420) | |||||||
| Balance | |||||||||
Cash | 577,583 | 481,271 | |||||||
Long term investments | 29,829 | 5,469 | |||||||
Excess cash | 607,412 | 486,740 | |||||||
Stockholders' equity | (902,174) | (693,839) | |||||||
Invested Capital | 1,458,005 | 1,162,449 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 70,371 | 60,761 | |||||||
Price | 21.61 -15.09% | 25.45 16.26% | |||||||
Market cap | 1,520,707 -1.66% | 1,546,365 31.74% | |||||||
EV | 916,565 | 1,061,947 | |||||||
EBITDA | (163,032) | (152,178) | |||||||
EV/EBITDA | |||||||||
Interest | 208 | 3,137 | |||||||
Interest/NOPBT | |||||||||